Literature DB >> 9209730

Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.

O Freudenreich1, R D Weiner, J P McEvoy.   

Abstract

Specific electroencephalogram (EEG) changes during clozapine therapy were prospectively studied in a cohort of 50 chronic state hospital patients with schizophrenia who were randomly assigned to one of three nonoverlapping clozapine serum level ranges (50-150 ng/mL, 200-300 ng/mL, and 350-450 ng/mL). EEGs were obtained before clozapine was instituted, and after 10 weeks of treatment. Fifty-three percent of patients showed EEG changes during the 10-week study period. We observed three seizures (6%), one in a patient on 900 mg (serum level 320 ng/mL) clozapine, and two in patients with lower clozapine serum levels (200-300 ng/mL) who had prior histories of seizures and inadequate valproate coverage. Thirteen percent of patients developed spikes with no relationship to dose or serum level of clozapine. Fifty-three percent of patients developed slowing on EEG. Compared to plasma levels below 300 ng/mL, a clozapine serum level between 350 and 450 ng/mL led to more frequent and more severe slowing. The EEG slowing correlated with observed sleepiness, although this factor was not sufficient to explain the severity of high-dose effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209730     DOI: 10.1016/S0006-3223(96)00298-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  21 in total

Review 1.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 2.  Clozapine dose for schizophrenia.

Authors:  Selvizhi Subramanian; Birgit A Völlm; Nick Huband
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

3.  Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice.

Authors:  Jason Smucny; Karen E Stevens; Jason R Tregellas
Journal:  Pharmacol Biochem Behav       Date:  2014-01-10       Impact factor: 3.533

Review 4.  Effects of psychotropic drugs on seizure threshold.

Authors:  Francesco Pisani; Giancarla Oteri; Cinzia Costa; Giorgio Di Raimondo; Raoul Di Perri
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

6.  Resting EEG deficits in accused murderers with schizophrenia.

Authors:  Robert A Schug; Yaling Yang; Adrian Raine; Chenbo Han; Jianghong Liu; Liejia Li
Journal:  Psychiatry Res       Date:  2011-08-06       Impact factor: 3.222

Review 7.  Seizure associated with clozapine: incidence, etiology, and management.

Authors:  Andrew M Williams; Susie H Park
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

8.  State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Authors:  Robert W Gould; Michael T Nedelcovych; Xuewen Gong; Erica Tsai; Michael Bubser; Thomas M Bridges; Michael R Wood; Mark E Duggan; Nicholas J Brandon; John Dunlop; Michael W Wood; Magnus Ivarsson; Meredith J Noetzel; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropharmacology       Date:  2015-11-23       Impact factor: 5.250

9.  Clozapine-related EEG changes and seizures: dose and plasma-level relationships.

Authors:  Seema Varma; Delia Bishara; Frank M C Besag; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2011-04

Review 10.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.